1118 related articles for article (PubMed ID: 31031702)
1. The Discovery and Development of Liraglutide and Semaglutide.
Knudsen LB; Lau J
Front Endocrinol (Lausanne); 2019; 10():155. PubMed ID: 31031702
[TBL] [Abstract][Full Text] [Related]
2. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
3. Clinical potential of treatment with semaglutide in type 2 diabetes patients.
Røder ME
Drugs Context; 2019; 8():212585. PubMed ID: 31844422
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin JA
Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
[TBL] [Abstract][Full Text] [Related]
5. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Lau J; Bloch P; Schäffer L; Pettersson I; Spetzler J; Kofoed J; Madsen K; Knudsen LB; McGuire J; Steensgaard DB; Strauss HM; Gram DX; Knudsen SM; Nielsen FS; Thygesen P; Reedtz-Runge S; Kruse T
J Med Chem; 2015 Sep; 58(18):7370-80. PubMed ID: 26308095
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
7. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Barritt AS; Marshman E; Noureddin M
Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
[TBL] [Abstract][Full Text] [Related]
9. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.
Williams DM; Staff M; Bain SC; Min T
touchREV Endocrinol; 2022 Mar; 18(1):43-48. PubMed ID: 35975210
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
12. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
[TBL] [Abstract][Full Text] [Related]
13. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B
Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
[TBL] [Abstract][Full Text] [Related]
14. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
16. Advances in GLP-1 treatment: focus on oral semaglutide.
Eliaschewitz FG; Canani LH
Diabetol Metab Syndr; 2021 Sep; 13(1):99. PubMed ID: 34526121
[TBL] [Abstract][Full Text] [Related]
17. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
[TBL] [Abstract][Full Text] [Related]
18. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 physiology informs the pharmacotherapy of obesity.
Drucker DJ
Mol Metab; 2022 Mar; 57():101351. PubMed ID: 34626851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
